Subcutaneous options offer convenience for patients — and a valuable window for drugmakers
From weight loss to cancer drugs, subcutaneous injections are popular with patients for their convenience, potentially ...
Indiatimes18d
Refex Industries Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In the first 100 days of Modi 3.0, Sensex surged 8.2% with BSE Smallcap up 18%. Top smallcaps like Refex Industries soared 221%. Investors are cautious due to tax hikes and policy risks.
pharmaphorum22d
AbbVie gets crucial US approval for psoriasis drug Skyrizi
The recommended dose for Skyrizi is 150 mg – administered by two subcutaneous injections every 12 weeks following two initiation doses at week 0 and 4. It can be administered in-office or by ...
The Hindu22d
IIT Bombay researchers develop painless needle-free shock syringes
In a welcome move for many patients who have a fear of needles, latest research by the Indian Institute of Technology Bombay (IIT Bombay) promises a painless syringe experience for all kinds of ...
India Today22d
IIT Bombay designs needle-free shock syringe for painless injections
IIT Bombay has developed needle-free shock syringes for painless, safe drug delivery, offering hope for a future without injection-related trauma. Tested on rats, it outperformed traditional needles ...
Radio Ink27d
AbbVie’s Skyrizi Rockets into Top 5 in Media Monitors Radio Report
This week also saw a notable surge from pharmaceutical company AbbVie, with their drug Skyrizi, which leaped from 32nd to 4th place. PayPal, T-Mobile, and Vicks also made solid showings ...
pharmaphorum1y
AbbVie’s Skyrizi hits the spot in refractory psoriasis
New data with AbbVie’s IL-23 inhibitor Skyrizi suggests it can alleviate symptoms in psoriasis patients who don’t respond well to other biologics for the skin disease, including widely-used IL ...